BTI
BMRN icon

Blue Trust Inc’s BioMarin Pharmaceuticals BMRN Stock Holding History

Blue Trust Inc’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.9K Hold
1,029
– – ﹤0.01% 1282
2026
Q1 		$58.1K Hold
1,029
– – ﹤0.01% 1258
2025
Q4 		$61.2K Sell
1,029
-27
-3% -$1.47K ﹤0.01% 1277
2025
Q3 		$57.2K Buy
1,056
+27
+3% +$1.54K ﹤0.01% 1351
2025
Q2 		$56.6K Buy
1,029
+41
+4% +$2.41K ﹤0.01% 1379
2025
Q1 		$69.8K Buy
988
+21
+2% +$1.41K ﹤0.01% 1165
2024
Q4 		$63.6K Buy
967
+108
+13% +$7.23K ﹤0.01% 1139
2024
Q3 		$70.7K Buy
859
+717
+505% +$59.9K ﹤0.01% 1413
2024
Q2 		$12.4K Buy
+142
New +$11.8K ﹤0.01% 1856
2024
Q1 		– Sell
-44
Closed -$4K – 2231
2023
Q4 		$4K Buy
44
+3
+7% +$265 ﹤0.01% 1896
2023
Q3 		$4K Sell
41
-1
-2% -$89 ﹤0.01% 1679
2023
Q2 		$4K Sell
42
-5
-11% -$471 ﹤0.01% 1572
2023
Q1 		$5K Buy
47
+41
+683% +$4.25K ﹤0.01% 1772
2022
Q4 		$1K Buy
+6
New +$563 ﹤0.01% 2015

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Blue Trust Inc's BMRN Position: Q2 2026 in Review

Blue Trust Inc held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 1,029 shares worth $58.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1282.

Blue Trust Inc first reported a position in BMRN in Q4 2022 and has held it in 14 quarters since. The position peaked at $70.7K in Q3 2024. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Blue Trust Inc held 1,029 shares of BioMarin Pharmaceuticals worth $58.9K as of Q2 2026.
  • Blue Trust Inc left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Blue Trust Inc's portfolio in Q2 2026, its #1282 holding.
  • Blue Trust Inc first reported a position in BioMarin Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • Blue Trust Inc's BioMarin Pharmaceuticals position peaked at $70.7K in Q3 2024.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.